To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis

Exclusion Criteria

• •Patients with non-allergic rhinitis, such as drug-induced rhinitis, vasomotor rhinitis, non-allergic rhinitis eosinophilic rhinitis, etc.; patients with severe nasal septum deviation, sinusitis, nasal polyps, hypertrophic rhinitis Other nasal organic lesions;
• •In the nasal examination at the end of the screening period or the introduction period, there is any erosion of the nasal mucosa, septal ulcer or perforation of the nasal septum;
• •Those who have undergone sinus surgery within 3 months before the screening period or who have not fully healed the nasal wound;
• •The subject has uncontrolled diabetes mellitus, that is, fasting blood glucose (FBG) \> 10mmol/L in the laboratory test during the screening period;
• •History of allergy to any study drug or similar chemical drugs (CRTh2 antagonists);
• •History of severe allergic reaction to any allergen, such as anaphylactic shock or life-threatening asthma, previous intubation, respiratory arrest, hospitalization for asthma or acute asthma attack within the past 3 months;
• •Those who were found to respond to placebo during the lead-in period (with rhinitis symptoms of moderate or above during the screening period, those with mild or no symptoms during the lead-in period, or baseline rTNSS mean \<6 points were defined as placebo responders;
• •Women who are pregnant or breastfeeding, or who plan to become pregnant or breastfeeding during the study period;
• •Any subject deemed unsuitable for participation in this clinical study by the investigator.